Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQPX4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $97,614
Award facts
- Contract value 100% obligated
- $97,613.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $97,613.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued on December 11, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9 billion ceiling value extending through December 31, 2036.
DMS Pharmaceutical Group supplies a comprehensive range of pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide, including specialty biologics, branded and generic medications, vaccines, and medical devices. The PPV-G GEN V represents a component of the Defense Logistics Agency's broader $30.3 billion pharmaceutical acquisition strategy designed to support recurring medical supply needs across military healthcare operations globally. The company's established performance across multiple delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system, with this Entyvio delivery order representing one of numerous purchases issued by the Defense Logistics Agency's Medical Supply Chain division in recent months.
Quick answers
Who was awarded contract SPE2DR26FQPX4?
SPE2DR26FQPX4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FQPX4 worth?
The government has obligated $97,614 on SPE2DR26FQPX4.
Is contract SPE2DR26FQPX4 an order under another contract?
Yes. SPE2DR26FQPX4 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPX4 competed?
The extent of competition for SPE2DR26FQPX4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award